vs
Side-by-side financial comparison of Agilent Technologies (A) and Surgery Partners, Inc. (SGRY). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $885.0M, roughly 2.0× Surgery Partners, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs -1.7%, a 18.7% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs 2.4%). Agilent Technologies produced more free cash flow last quarter ($175.0M vs $90.6M). Over the past eight quarters, Surgery Partners, Inc.'s revenue compounded faster (11.1% CAGR vs 6.9%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
United Surgical Partners International, Inc. (USPI) is an American ambulatory care company based in Dallas, Texas. It was founded by Don Steen in 1998.
A vs SGRY — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $885.0M |
| Net Profit | $305.0M | $-15.0M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | 12.5% |
| Net Margin | 17.0% | -1.7% |
| Revenue YoY | 7.0% | 2.4% |
| Net Profit YoY | -4.1% | 86.2% |
| EPS (diluted) | $1.07 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $885.0M | ||
| Q3 25 | $1.7B | $821.5M | ||
| Q2 25 | $1.7B | $826.2M | ||
| Q1 25 | $1.7B | $776.0M | ||
| Q4 24 | $1.7B | $864.4M | ||
| Q3 24 | $1.6B | $770.4M | ||
| Q2 24 | $1.6B | $762.1M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-15.0M | ||
| Q3 25 | $336.0M | $-22.7M | ||
| Q2 25 | $215.0M | $-2.5M | ||
| Q1 25 | $318.0M | $-37.7M | ||
| Q4 24 | $351.0M | $-108.5M | ||
| Q3 24 | $282.0M | $-31.7M | ||
| Q2 24 | $308.0M | $-15.5M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 12.5% | ||
| Q3 25 | 20.7% | 12.9% | ||
| Q2 25 | 18.0% | 13.5% | ||
| Q1 25 | 22.4% | 8.0% | ||
| Q4 24 | 24.0% | 14.7% | ||
| Q3 24 | 21.1% | 7.9% | ||
| Q2 24 | 23.1% | 11.1% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -1.7% | ||
| Q3 25 | 19.3% | -2.8% | ||
| Q2 25 | 12.9% | -0.3% | ||
| Q1 25 | 18.9% | -4.9% | ||
| Q4 24 | 20.6% | -12.6% | ||
| Q3 24 | 17.9% | -4.1% | ||
| Q2 24 | 19.6% | -2.0% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-0.11 | ||
| Q3 25 | $1.18 | $-0.18 | ||
| Q2 25 | $0.75 | $-0.02 | ||
| Q1 25 | $1.11 | $-0.30 | ||
| Q4 24 | $1.23 | $-0.86 | ||
| Q3 24 | $0.97 | $-0.25 | ||
| Q2 24 | $1.05 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $239.9M |
| Total DebtLower is stronger | $3.0B | $3.6B |
| Stockholders' EquityBook value | $6.9B | $1.7B |
| Total Assets | $12.8B | $8.1B |
| Debt / EquityLower = less leverage | 0.44× | 2.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $239.9M | ||
| Q3 25 | $1.5B | $203.4M | ||
| Q2 25 | $1.5B | $250.1M | ||
| Q1 25 | $1.5B | $229.3M | ||
| Q4 24 | $1.3B | $269.5M | ||
| Q3 24 | $1.8B | $221.8M | ||
| Q2 24 | $1.7B | $213.5M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $3.6B | ||
| Q3 25 | $3.4B | $3.5B | ||
| Q2 25 | $3.3B | $3.5B | ||
| Q1 25 | $3.3B | $3.4B | ||
| Q4 24 | $3.3B | $3.3B | ||
| Q3 24 | $2.1B | $3.1B | ||
| Q2 24 | $2.1B | $3.0B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $1.7B | ||
| Q3 25 | $6.4B | $1.7B | ||
| Q2 25 | $6.1B | $1.7B | ||
| Q1 25 | $6.0B | $1.7B | ||
| Q4 24 | $5.9B | $1.8B | ||
| Q3 24 | $5.9B | $1.9B | ||
| Q2 24 | $6.2B | $2.0B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $8.1B | ||
| Q3 25 | $12.2B | $7.9B | ||
| Q2 25 | $12.2B | $8.0B | ||
| Q1 25 | $11.9B | $7.9B | ||
| Q4 24 | $11.8B | $7.9B | ||
| Q3 24 | $11.0B | $7.5B | ||
| Q2 24 | $10.9B | $7.5B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 2.10× | ||
| Q3 25 | 0.53× | 2.00× | ||
| Q2 25 | 0.55× | 1.98× | ||
| Q1 25 | 0.56× | 1.98× | ||
| Q4 24 | 0.57× | 1.83× | ||
| Q3 24 | 0.36× | 1.63× | ||
| Q2 24 | 0.34× | 1.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $103.4M |
| Free Cash FlowOCF − Capex | $175.0M | $90.6M |
| FCF MarginFCF / Revenue | 9.7% | 10.2% |
| Capex IntensityCapex / Revenue | 5.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | $195.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $103.4M | ||
| Q3 25 | $362.0M | $83.6M | ||
| Q2 25 | $221.0M | $81.3M | ||
| Q1 25 | $431.0M | $6.0M | ||
| Q4 24 | $481.0M | $111.4M | ||
| Q3 24 | $452.0M | $65.2M | ||
| Q2 24 | $333.0M | $82.8M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $90.6M | ||
| Q3 25 | $259.0M | $63.8M | ||
| Q2 25 | $107.0M | $57.9M | ||
| Q1 25 | $334.0M | $-16.7M | ||
| Q4 24 | $388.0M | $89.1M | ||
| Q3 24 | $360.0M | $45.0M | ||
| Q2 24 | $230.0M | $55.9M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 10.2% | ||
| Q3 25 | 14.9% | 7.8% | ||
| Q2 25 | 6.4% | 7.0% | ||
| Q1 25 | 19.9% | -2.2% | ||
| Q4 24 | 22.8% | 10.3% | ||
| Q3 24 | 22.8% | 5.8% | ||
| Q2 24 | 14.6% | 7.3% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 1.4% | ||
| Q3 25 | 5.9% | 2.4% | ||
| Q2 25 | 6.8% | 2.8% | ||
| Q1 25 | 5.8% | 2.9% | ||
| Q4 24 | 5.5% | 2.6% | ||
| Q3 24 | 5.8% | 2.6% | ||
| Q2 24 | 6.5% | 3.5% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
SGRY
| Private Insurance | $460.5M | 52% |
| Government Revenue | $368.6M | 42% |
| Other | $19.8M | 2% |
| Self Pay Revenue | $19.6M | 2% |
| Other Patient Service Revenue Sources | $16.5M | 2% |
